-There certainly appears to be a market for oral vaccines. However, it may be years before the company delivers a product to meet that opportunity.
-VXRT stock has been dropping significantly after the company released data on its Phase 1 study. The results werenât bad, but not what analysts were expecting. Vaxart CEO Andrei Floroiu stated, âOur vaccineâs immune response appears very different than that seen from the leading injectablesâŠâ
-Time will tell if that is a better approach. But time is not on Vaxartâs side at least as it relates to Covid-19. With each passing day, more Americans become fully vaccinated. And in one of its latest announcements this week, the Center for Disease Control (CDC) said that data suggests individuals who have recovered from even a mild case of Covid-19 may have long-lasting antibody production. This would reduce, or altogether eliminate, the need for those individuals to be vaccinated.
-The good news is the company has several other vaccine candidates in their pipeline. However, none of those candidates are further along than its Covid-19 candidate.
-It should be obvious that any investor looking to take a position in VXRT stock should keep their position small. Vaxart does not yet have a product thatâs in market and it could be several years before they do.
-VXRT stock has been dropping significantly after the company released data on its Phase 1 study. The results werenât bad, but not what analysts were expecting. Vaxart CEO Andrei Floroiu stated, âOur vaccineâs immune response appears very different than that seen from the leading injectablesâŠâ
-Time will tell if that is a better approach. But time is not on Vaxartâs side at least as it relates to Covid-19. With each passing day, more Americans become fully vaccinated. And in one of its latest announcements this week, the Center for Disease Control (CDC) said that data suggests individuals who have recovered from even a mild case of Covid-19 may have long-lasting antibody production. This would reduce, or altogether eliminate, the need for those individuals to be vaccinated.
-The good news is the company has several other vaccine candidates in their pipeline. However, none of those candidates are further along than its Covid-19 candidate.
-It should be obvious that any investor looking to take a position in VXRT stock should keep their position small. Vaxart does not yet have a product thatâs in market and it could be several years before they do.